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Abstract
Myocardial infarction (MI) induces a complex inflammatory immune response, followed by the remodelling of the heart muscle and scar forma-
tion. The rapid regeneration of the blood vessel network system by the attraction of hematopoietic stem cells is beneficial for heart function.
Despite the important role of chemokines in these processes, their use in clinical practice has so far been limited by their limited availability over
a long time-span in vivo. Here, a method is presented to increase physiological availability of chemokines at the site of injury over a defined
time-span and simultaneously control their release using biodegradable hydrogels. Two different biodegradable hydrogels were implemented, a
fast degradable hydrogel (FDH) for delivering Met-CCL5 over 24 hrs and a slow degradable hydrogel (SDH) for a gradual release of protease-
resistant CXCL12 (S4V) over 4 weeks. We demonstrate that the time-controlled release using Met-CCL5-FDH and CXCL12 (S4V)-SDH sup-
pressed initial neutrophil infiltration, promoted neovascularization and reduced apoptosis in the infarcted myocardium. Thus, we were able to
significantly preserve the cardiac function after MI. This study demonstrates that time-controlled, biopolymer-mediated delivery of chemokines
represents a novel and feasible strategy to support the endogenous reparatory mechanisms after MI and may compliment cell-based therapies.
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Introduction
Myocardial infarction (MI), following the occlusion of an atheroscle-
rotic coronary artery, causes death of the cardiomyocytes and initia-
tion of an inflammatory reaction, activation of the nuclear factor (NF)-
jB and toll-like receptor (TLR)-mediated pathways, up-regulation of
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chemokines, cytokines as well as adhesion molecules in endothelial
cells and leucocytes [1]. All these processes lead to the infiltration of
polymorphonuclear cells, monocytes and lymphocytes into the
infarcted area and are of crucial importance in the proper healing and
scar formation. Neutrophil- and macrophage-derived inflammatory
signals initiate the phagocytosis of dead cells and matrix degradation
products. During the proliferation phase, the expression of inflamma-
tory mediators is inhibited; the fibroblasts and endothelial cells infil-
trate into the infarcted area and promote collagen deposition and
angiogenesis. The cardiac repair, or so-called ‘remodeling’, of the
heart muscle is in fact the replacement of the adjacent myocardium
with connective tissue and consecutive dilation of the ventricles [1, 2].
Despite the extensive progress in the past decades, current clini-
cal therapies are not always efficient in reducing myocardial necrosis
and optimizing cardiac repair following infarction. New strategies
have been proposed such as progenitor cell therapy, which was con-
sidered as a promising therapeutic approach to provide an alternative
way to regenerate the heart structure after MI. Pioneering studies in
animals have shown that transplantation of adult stem cells after
acute MI improves neovascularization and reduces fibrosis, preserv-
ing the left ventricular (LV) heart function [3, 4]. Unfortunately, these
promising results were less pronounced in clinical studies in patients
[5], probably because of the difficult translation of the experimental
findings from the animal to the human system. New data suggest that
an additional mechanism of improving the heart function by cell-
based therapies can be ascribed to inflammation and its consecutive
effects [6]. These findings are of significance, suggesting that we can
potentially improve the outcome after cell therapy by selectively con-
trolling and manipulating not only the trafficking and behaviour of the
transplanted cells but also the inflammatory reaction through the
modulation of chemokine responses [2].
Chemokines are small signalling proteins that regulate the traffick-
ing of a large variety of cell types [7]. They can both prevent apoptosis
of cardiomyocytes and promote angiogenesis in the infarcted area [2].
The inhibition of neutrophil infiltration by blocking CCR1 or by Met-
CCL5 (Met-RANTES) treatment leads to improved LV function and
reduction in infarct extension [8, 9], possibly by decreasing myeloper-
oxidase expression and preventing further increase in the resulting tis-
sue damage [10]. CXCL12 (Stromal Cell-Derived Factor 1/SDF-1) and
its protease-resistant mutants are well-established agents for recruit-
ing hematopoietic stem cells from the circulating blood, resulting in a
significant increase in vessel formation, vascularization in the scar tis-
sue and a consecutive improvement of LV function after MI [11–13].
In this study, we propose a novel combined approach using
biodegradable synthetic hydrogels [14, 15] to achieve spatially and
temporally controlled delivery of Met-CCL5 and recombinant prote-
ase-resistant CXCL12 (S4V), two established agents that inhibit neu-
trophil infiltration and improve hematopoietic stem cell recruitment to
sustain neovascularization respectively. A very rapid biodegradable
hydrogel assured a faster release and action of Met-CCL5 to block
neutrophil infiltration during the first hours. A second slower biode-
gradable hydrogel served to ensure a longer term release and action
of CXCL12 (S4V) to attract hematopoietic stem cells over several
weeks. Thus, this presents a novel approach for the prevention of
tissue damage after MI.
Materials and methods
Construction of CXCL12 and Met-CCL5
expression plasmids
The DNA sequence of CXCL12 was cloned from mouse peripheral blood
mononuclear cells (PBMC) cDNA into the pBluescript II KS (Stratagene,
La Jolla, CA, USA) and mutations were applied in the N-terminus using
QuikChange II site–directed mutagenesis kit (Stratagene) according to
manufacturer’s instructions. This resulted in CXCL12 (S4V) variant and
inactive control CXCL12 (S2G4V) resistant to MMP-2 and DPPIV enzy-
matic cleavage as reported previously by Segers et al. [13]. The cDNAs
were subcloned into pET32a (Merck, Darmstadt, Germany) for expres-
sion as thioredoxin fusion proteins in Escherichia coli (see below). For
the same purpose, Met-CCL5 was ordered as a codon-optimized syn-
thetic gene cloned in pET26+ (Merck) from Genscript (Piscataway, NJ,
USA). Detailed procedures can be found in the online supplementary
information.
Expression and purification of recombinant
chemokines
The recombinant chemokines were expressed in and purified from
E. coli Rosetta DE3 (Merck) as described previously [16–18]. After puri-
fication, the chemokines were dialysed in >100 volumes of 0.01% triflu-
oroacetic acid and lyophilized for long-term storage.
Isolation of early-outgrowth cells and neutrophils
from peripheral blood
Angiogenic early-outgrowth cells (EOC) were isolated according to
established protocols [19–21] from citrate/dextran anticoagulated
peripheral blood buffy coats of healthy volunteers. Peripheral blood
mononuclear cells were separated by density gradient centrifugation
with Biocoll (Merck). The PBMC were washed twice with PBS, resus-
pended in endothelial cell growth medium MV2 and plated on fibronec-
tin-coated (10 lg/ml) 6-well plates (107 cells per well). At day 4, the
medium was changed and the adherent cells were detached with Accu-
tase for 5 min. at 37°C, counted and subjected for activity assay at day
5–7. Neutrophils were isolated from blood collected in the presence of
EDTA (1.6 mg EDTA/ml blood) according to established protocols using
PolymorphprepTM (Axis-Shield, Oslo, Norway). Experiments with human
material were approved by the local ethics board and all individuals
gave informed consent.
Chemotaxis experiments
Activities of purified CXCL12 (S4V), CXCL12 (S2G4V) and Met-CCL5
were assayed by migration of EOC (for CXCL12 variants) or neutrophils
(for Met-CCL5) and compared with commercially available chemokines.
CXCL8 is an established neutrophil attractant and used as positive control
for neutrophil adhesion. Cells (500,000 cells/ml) were added to the upper
well of 6.5 mm transwellTM inserts with 8.0 lm pore polycarbonate
membranes (Costar, Tewksbury, MA, USA), and chemokines (200 ng/ml)
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
791
J. Cell. Mol. Med. Vol 18, No 5, 2014
were added to the lower wells. Cells were counted by flow cytometry
(FACS Canto II; BD Biosciences, San Jose, CA, USA) in the lower well
after 1 hr (neutrophils) or 3 hrs (EOC). All experiments were performed
in triplicate.
Cell adhesion assays under flow conditions
Flow-resistant adhesion on endothelial cells in response to recombinant
chemokines was assessed in customized flow chambers as described
by Postea et al. [18]. Briefly, Jurkat T lymphoma cells or neutrophils
were labelled by the addition of calcein (1 lM; Life Technologies, Carls-
bad, CA, USA). Chemokines were added (200 ng/ml) and incubated for
5 min. at 37°C. Human umbilical vein endothelial cells (HUVEC), cul-
tured in 35-mm dishes, were activated with tumour necrosis factor-a
(10 ng/ml) for 4 hrs and assembled into flow chambers. Cells (500,000
cells/ml) were perfused for 3 min. at a wall shear stress of 1.5 dynes/
cm2 in Hank’s buffer containing HEPES (10 mmol/l), CaCl2 and MgCl2
(1 mmol/l each) and 0.5% human albumin (Baxter, Deerfield, IL, USA)
subsequently followed by video microscopic quantification of adherent
fluorescent cells. Adherent cell were manually counted in at least six
fields and expressed as cells/mm2.
Synthesis of biodegradable hydrogels
The synthesis of hydrogels from thiol-functionalized biodegradable sP
(EO-stat-PO) pre-polymer was performed as described previously [22].
Simple oxidation of thiolated pre-polymer by H2O2 resulted into fast
degradable hydrogel (FDH) with disulphide bonds, while the crosslinking
of thiols by Michael addition with added PEG-diacrylate resulted in a
slowly degrading hydrogel (SDH; Fig. S1) with thioether bonds.
Release of CXCL12 (S4V) and Met-CCL5 from
biodegradable hydrogels
Slowly degrading and fast degrading hydrogels (15 ll) containing
3 lmol/l CXCL12 (S4V) or 0.5 lmol/l Met-CCL5, respectively, were
incubated with 250 ll PBS without or with 5 mmol/l reduced glutathi-
one (Sigma-Aldrich, St. Louis, MO, USA) and incubated over 4 weeks
(SDH) or 24 hrs (FDH). At suitable time-points, 250 ll PBS containing
5 mmol/l reduced glutathione was replaced and the supernatant was
analysed by DuoSet ELISA kits (R&D Systems, Minneapolis, MN, USA)
for mouse CXCL12/SDF-1 or human CCL5/RANTES according to the
manufacturer’s instructions.
Biocompatibility of CXCL12 (S4V), Met-CCL5 and
biodegradable polymers
Human umbilical vein endothelial cells were seeded in collagen-
G–coated 96-well plates with Endothelial Cell Growth Medium (PromoCell,
Heidelberg, Germany) and cells were allowed to attach prior to treat-
ment with 5 lg/ml CCL5, 30 lg/ml CXCL12 (S4V) and 0.45 g/ml biode-
gradable hydrogels. Proliferation between 0 and 72 hrs was determined
using BrdU Proliferation Assay (Novagen/Merck Bioscience, Darmstadt,
Germany) and cytotoxicity was detected using the CellTiter-Blue cell
viability assay (Promega, Mannheim, Germany) at time-points ranging
from 0 to 24 hrs. All procedures were performed according to the man-
ufacturer’s instructions. The data were expressed as the relative signals
(RFU) after subtraction of the signals of the appropriate buffer or med-
ium controls.
Mouse model of myocardial infarction and
injection of biodegradable hydrogels containing
chemokines
Eight-week-old male littermate C57BL/6 mice (25–26 g, n = 6–9 per
group) were randomly subjected to coronary occlusion as described
earlier [9, 23]. Only mice dying during the operation as a result of the
surgery complications were excluded from the statistical measurements.
Briefly, mice were intubated under general anaesthesia (using ketamine
and xylazine) and positive pressure ventilation was maintained using a
rodent respirator. Hearts were exposed by left thoracotomy and MI is
induced by suture occlusion of the left anterior descending artery over
a silicone tube. Biodegradable hydrogels SDH and FDH (15 ll) were
mixed with crosslinking agent and loaded with buffer or 0.5 lg Met-
CCL5 and/or 3 lg CXCL12 (S4V) and subsequently injected separately
in a standardized manner, using a 36-gauge needle into two directly
adjacent sites of the mouse myocardium at the border of the infarct
area directly after inducing MI. Control mice (n = 6) received MI with
injected PBS in equal volumes. Hydrogels are not thermo-responsive;
the components are mixed shortly before transplantation and will gel on
site immediately after injection. Fast degradable hydrogel degrades in
24 hrs in vivo, whereas SDH needs 4 weeks for complete degradation.
The gels do not evoke immune reactions and some studies describe
anti-inflammatory properties of the gels [14, 15]. Therefore, control
groups with or without gels were included. The muscle layer and skin
incision were closed with a silk suture, after polymerization was com-
plete. The animals were treated with a single dose of buprenorphine
(0.1 mg/ml) and kept under standard conditions 1 day or 4 weeks after
MI until further investigation. Heart function of the mice was evaluated
by echocardiography 1 day before, and 4 weeks after MI. All animal
experiments and study protocols were approved by local authorities,
complying with Romanian animal protection laws.
Quantitative immunohistochemistry and
immunofluorescence
The infarcted area was determined in serial sections (5 lm) of the
infarcted myocardium (10 sections per mouse) after staining with Go-
mori’s 1-step trichrome staining using Diskus software (Hilgers,
K€onigswinter, Germany) and expressed as percentage of LV area. The
number of neutrophils (naphthol-AS-D-chloroacetate esterase and anti-
MPO, #RB-373-A; Thermo Scientific, Waltham, MA, USA) was deter-
mined 1 day after MI, whereas the endothelial cells (CD31, #M20;
Santa Cruz, Santa Cruz, CA, USA) was determined in formalin-fixed
serial sections (three per mouse, 200 lm apart) of the infarcted myo-
cardium 4 weeks after MI. Positive-stained cells were numbered in six
different fields from infarcted area per section and expressed as cells/
mm2. Blood vessels positive for CD31 were quantified and expressed
as CD31/mm2. Apoptotic (TUNEL, TMRred; Roche, Mannheim, Germany)
and proliferating (Ki67, clone TEC-3; DAKO, Hamburg, Germany) cells
were stained, counted and expressed as per cent from total cells
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(DAPI staining). Total Akt (Akt1/2 (N-19), sc-1619; Santa Cruz) and
phosphorylated-Akt (phospho-Akt (Ser) (193H12), #4058S; Cell Signal-
ing Technologies, Beverly, MA, USA) were stained using Dylight 488–
conjugated secondary antibodies (Thermo Scientific).
Echocardiographic measurements
Two-dimensional and M-mode echocardiographic measurements (Vevo
770; Visual Sonics, Toronto, ON, Canada) were performed before and
4 weeks after induction of MI. Mice are anesthetized with 1.5% isoflura-
ne (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane) via mask and
placed in supine position on a warming pad. The ejection fraction (EF)
was recorded and analysed in long axis and orthogonally in the short
axis; the average of both results was used for further analysis [23]. LV
dimensions in systole and diastole were also measured using M-Mode
in the short axis (Table 1A and B).
Statistical analysis
Data were represented as mean value  SE. Data analysis was per-
formed with Prism 4 software (Graph Pad Software, San Diego, CA,
USA) using one-way parametric ANOVA followed by Newman-Keuls post
hoc testing or Kruskall–Wallis non-parametric testing with Dunn’s post
hoc comparison, where appropriate. Differences with P < 0.05 were
considered significant.
Results
Generation and functional analysis of
chemokines and biodegradable gels
Recombinant Met-CCL5, CXCL12 (S4V) and CXCL12 (S2G4V) were
expressed in and purified from E. coli. SDS-page, western blot and
MALDI-TOF analysis confirmed the purities (>95%), identity and the
expected masses of 7.98, 8.07 and 8.03 kD for Met-CCL5, CXCL12
(S4V) and CXCL12 (S2G4V; Figs S2 and 3). The activities of the
recombinant chemokines were assessed using cell-recruitment
assays with the designated target cell types. Isolated neutrophils
stimulated with CXCL8 and/or CCL5 showed considerable chemotaxis
and flow-resistant adhesion to HUVEC (Fig. 1A and B). Met-CCL5
specifically blocked the action of CCL5, but not of CXCL8 (an estab-
lished neutrophil attractant). The recombinant CXCL12 (S4V) induced
the migration of angiogenic EOC to a slightly lower extent than
CXCL12 wild-type, whereas the activity of CXCL12 (S2G4V) was com-
parable with the negative control (Fig. 1C). However, the adhesion of
CXCL12 (S4V)-stimulated Jurkat cells onto HUVEC under flow condi-
tions was comparable with CXCL12 wild-type. CXCL12 (S2G4V)
showed significantly less adhesion compared with the CXCL12 (S4V)
and CXCL12 wild-type (Fig. 1D). Neither treatment with Met-CCL5
nor with CXCL12 (S4V) impaired the proliferation and viability of cul-
tured HUVEC cells (Fig. S4A–D).
Table 1 Echocardiographic baseline measurements (n = 6-9 mice; A). Echocardiographic parameters 4 weeks after MI (B)
Control FDH SDH Met-CCL5-FDH CXCL12-SDH Met-CCL5-FDH CXCL12-SDH
(A)
EF (%) 59.2  3.08 57.3  3.33 56.7  1.02 53.8  0.82 55.6  1.13
Diastolic LVD (mm) 3.97  0.25 3.73  0.19 3.34  0.16 3.75  0.22 3.85  0.12
Systolic LVD (mm) 2.90  0.28 2.91  0.21 2.57  0.10 2.92  0.26 2.92  0.11
Heart rate (BMP) 410  29.8 380  23.3 403  24.4 379  10.9 371  7.73
Heart weight (mg) 99  4.60 106  10.8 95  6.01 98  14.7 107  6.19
(B)
EF (%) 35.8  1.85*** 31.6  1.30 41.3  2.31** 40.5  1.83*** 50.1  1.59*
Diastolic LVD (mm) 5.66  0.28 6.48  0.15 6.35  0.37 5.87  0.62 6.56  0.10
Systolic LVD (mm) 4.57  0.49 5.52  0.22 4.88  0.46 4.53  0.57 4.74  0.45
Heart rate (BMP) 442  11.4 426  38.2 501  36.7 502  34.4 414  34.9
Heart weight (mg) 107  6.58 119  7.93 100  8.77 104  6.70 103  4.86
*P < 0.01, 0.001 versus FDH SDH respectively; n = 6–9; **, ***P < 0.01, 0.001 versus Met-CCL5-FDH+CXCL12 (S4V)-SDH, respectively;
n = 6–9 mice; ANOVA.
EF: ejection fraction; LVD: left ventricular diameter; FDH: fast degradable hydrogel; SDH: slow degradable hydrogel; MIL: myocardial infarction.
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To control the local release of the protease-resistant CXCL12 and
Met-CCL5, two different biodegradable hydrogels were utilized. Six
arm, star-shaped polymers with copolymerized ethylene oxide and
propylene oxide in the ratio of 4 to 1, termed sP(EO-stat-PO), were
chosen as precursors for both types of hydrogel. Of six arms of the
polymer, three were functionalized with thiol groups, which were
crosslinked in two ways, resulting in FDH or SDH respectively
(Fig. S1). The FDH is used for the formulation with Met-CCL5 for a
quick release to inhibit neutrophil infiltration within the first hour after
MI. This fast release of Met-CCL5 from FDH was confirmed by incu-
bation in PBS and 5 mmol/l glutathione, which led to complete degra-
dation of the gel after 24 hrs (Fig. 1E) as a result of disulphide bond
cleavage. The SDH was conceived for formulation with the protease-
resistant CXCL12 (S4V) for a gradual release to recruit hematopoietic
stem cells from the circulating blood during a time period of 4 weeks
after MI. To confirm the release rate, the CXCL12 (S4V)-SDH was
incubated for 33 days in PBS to detect the local release over time.
After 33 days, the SDH was entirely degraded because of the hydro-
lytic cleavage of ester bonds in the backbone and release of chemoki-
ne was no longer detected (Fig. 1F). Proliferation and viability of
HUVEC were not affected by culturing in the presence of the thiolated
polymer (Fig. 4E and F).
Improvement of cardiac function after MI in mice
by combined treatment with the protease-
resistant CXCL12 and Met-CCL5
To investigate a possible beneficial role of a blocked short-term neu-
trophil influx after cardiac ischaemia combined with a longer term
recruitment of hematopoietic cells, the chemokine-loaded hydrogels
were applied in an experimental model of MI. During hydrogel treat-
ment, the levels of CXCL12 (S4V) in mouse sera after 1 day and
4 weeks were not increased (Fig. 5A and B), because of the very slow
release rate from the hydrogel and the local application. Human Met-
CCL5 levels were increased after 1 day of treatment with Met-CCL5–
A B
C D
E F
Fig. 1 In vitro studies of recombinant
chemokines. (A) Chemotaxis assay of
neutrophils towards Met-CCL5, CCL5 wild-
type and commercially available CXCL8
wild-type. (B) Adhesion assay under flow
on activated human umbilical vein endo-
thelial cells (HUVEC) using Met-CCL5-,
CCL5 wild-type and CXCL8-stimulated
neutrophils. (C) Chemotactic index of
angiogenic early-outgrowth cells towards
CXCL12 (S4V and S2G4V) and commer-
cially available CXCL12 wild-type. (D)
Adhesion assay using CXCL12 (S4V and
S2G4V)-stimulated Jurkat cells on acti-
vated HUVEC under flow conditions in
comparison with the commercially avail-
able CXCL12 wild-type. (E) Release of the
Met-CCL5 chemokine from the fast
degradable hydrogel over 24 hrs and (F)
of the CXCL12 (S4V) chemokine from the
slow degradable hydrogel over 33 days.
Depicted P values are based on paramet-
ric (A, B, D) or non-parametric (C) ANOVA
(n = 6–9).
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containing FDH (Fig. S5C), because of the quick release of human
Met-CCL5 from these hydrogels. As expected, the human Met-CCL5
was no longer detected in the mouse sera after 4 weeks (Fig. S5D).
The concentrations of mouse CCL5 in sera were slightly increased
after administration of any hydrogel variant (Fig. S5E and F).
After 4 weeks, the infarcted area was notably reduced in the
CXCL12 (S4V)-SDH (13.4  2.85%) and in the combined Met-CCL5-
FDH+CXCL12 (S4V)-SDH group (12.8  4.18%), compared with the
groups that received hydrogel only (30.7  5.51%) and Met-CCL5-
FDH (25.7  4.73%; Fig. 2A and B). Administration of the hydrogel
itself did not affect infarct size, as the infarcted area of the control
group was similar (30.3  3.72%; Fig. 2A and B).
The EF was increased in the group with Met-CCL5-FDH and
CXCL12 (S4V)-SDH in comparison with the hydrogel and control
group, but the combined treatment with Met-CCL5-FDH + CXCL12
(S4V)-SDH showed the highest preservation of the heart function
comparing with all other groups (Fig. 2C, Table 1). No changes in
baseline parameters (before MI, Table 1A), as well as in heart weight
and systolic or diastolic LV diameters before (Table 1A) and 4 weeks
after MI, were observed between the treated groups (Table 1B). How-
ever, evaluation of the functional parameters of the heart revealed a
significant improvement of cardiac function in the Met-CCL5-FDH +
CXCL12 (S4V)-SDH group that received a combined treatment
(Table 1B and Fig. 2C).
The same applied for neutrophil recruitment (Fig. 3) and neovas-
cularization (Fig. 4). The immediate infiltration of MI-induced neu-
trophils in the infarcted area (1 day after MI) was reduced in both the
Met-CCL5-FDH (272  35.8 per mm2) and the Met-CCL5-
FDH+CXCL12 (S4V)-SDH groups (299  33.6 per mm2), but not in
the CXCL12 (S4V)-SDH group (876  235.9 per mm2), compared
with the control groups that received only hydrogel (810  51.3 per
mm2) or PBS (760.7  72.2 per mm2; Fig. 3A and B). Similar results
were obtained by staining with anti-MPO antibody (Fig. 3C and D),
confirming the specificity of the administration of the CCR1 and CCR5
antagonist Met-CCL5 for the prevention of neutrophil recruitment.
Similarly, neovascularization 4 weeks after MI was also improved
in both the CXCL12 (S4V)-SDH (788  28.8 per mm2) and the Met-
CCL5-FDH+CXCL12 (S4V)-SDH groups (1022  63.1 per mm2), to a
higher extent as the Met-CCL5-FDH (466  29.4 per mm2), hydrogel
group (328  32.5 per mm2) and control groups (407  62.4 per
mm2), as quantified by CD31-staining (Fig. 4A and B). This indicates
a CXCL12 (S4V)-mediated increase in angiogenesis in infarcted myo-
cardium, supporting our hypothesis. To further investigate the pro-
angiogenic signalling, we performed immunohistological staining for
the downstream of CXCL12-induced activation of Akt (through phos-
phorylated-Akt) and we observed a higher activation after CXCL12
(S4V) and Met-CCL5-FDH+CXCL12 (S4V), 1 day after MI (Fig. 4C)
sustaining even up to 4 weeks after MI (Fig. 4D), compared with con-
trol and Met-CCL5–treated groups. These findings suggest that the
effects mediated by the CXCL12/CXCR4 pathway, e.g. the recruitment
of hematopoietic cells and the activation of angiogenic pathways,
would serve to reduce infarct size in our study rather than the block-
ade of initial neutrophil infiltration.
Finally, we did not observe significant differences in (endothelial
cell and cardiomyocyte) proliferation, 1 day and 4 weeks after MI,
despite a trend towards increased Ki67-staining in the CXCL12 (S4V)
A
B C
Fig. 2 Assessment of cardiac tissue damage and function after experimental myocardial infarction (MI). Representative Gomori-stained sections of
the hearts (A) and histomorphometric quantifications (B) of Control, fast degradable hydrogel slow degradable hydrogel (FDH SDH), Met-CCL5-FDH,
CXCL12 (S4V)-SDH and Met-CCL5-FDH CXCL12 (S4V)-SDH-treated mice (n = 6–9 per group), 4 weeks after MI. Echocardiographic measurements
of ejection fraction (EF; C) of Control, FDH SDH, Met-CCL5-FDH, CXCL12 (S4V)-FDH and Met-CCL5-FDH+CXCL12 (S4V)-FDH-treated mice (n = 6–9
per group), 4 weeks after MI. Depicted P values are based on ANOVA.
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and Met-CCL5-FDH+CXCL12 (S4V) groups compared with the control
group (Fig. 5A and B). However, all chemokine-treated groups
showed less apoptotic cells than the control at the end-points of the
study (Fig. 5C and D) suggesting an accelerated wound healing in
these groups.
Discussion
Chemokines modulate all phases of MI, having a decisive role in ven-
tricular remodelling, healing and scar formation [1, 2]. Some of them
with cardioprotective functions (e.g. CCL2, CXCL12, Macrophage
Migration Inhibitory Factor) are rapidly up-regulated to rescue the
cardiomyocytes from the imminent ischemic injury. Other chemokin-
es initiate an inflammatory reaction, recruiting neutrophils (CCR1-
ligands) or inflammatory monocytes (CCR2-ligands) that clean the
injured area from cellular debris. Later, chemokines, e.g. CX3CL1 or
CCR5-ligands, promote healing by stimulating collagen deposition
and angiogenesis [1, 2].
In this context, we have proposed a novel strategy of combining
the Met-CCL5 and protease-resistant CXCL12 treatments, for the
simultaneous activation of two important mechanisms for preserva-
tion of heart function: inhibition of neutrophil infiltration and
enhanced neovascularization by increasing the recruitment of hema-
topoietic stem cells. Met-CCL5 antagonizes CCR1 and CCR5 activa-
tion and function in response to their natural ligands CCL3-5, and this
blockade is able to reduce inflammation in models of induced inflam-
matory and autoimmune diseases, but also after MI [8]. Recombinant
Met-CCL5 chemokine was formulated in a synthetic, biodegradable
hydrogel for a fast release and was shown to reduce inflammation
and the migration of neutrophils during the first hours after MI. Com-
bined treatment with CXCL12 (S4V) in a slowly degrading gel
improved the heart function, decreased infarction area and increased
capillary density 4 weeks after MI compared with control group.
Currently, the majority of small and large molecular drugs are
delivered into patients systemically (e.g. oral or intravenous release)
without the use of a scaffold. Consequently, large doses are usually
required for a desired local effect because of non-specific uptake of
other tissue, which can lead to serious side effects. Thus, biodegrad-
able hydrogels are utilized here to stabilize and deliver bioactive mole-
cules in the desired tissue for a better dose monitoring and an exact
release [14] allowing a local and specific release of Met-CCL5 and
protease-resistant CXCL12 into the heart tissue over 24 hrs or
4 weeks respectively. Natural CXCL12 was broadly used in models of
MI. However, we found that the injection of CXCL12 after MI has only
limited results [24]. One reason for the inefficiency of natural CXCL12
A B
C D
Fig. 3 Assessment of neutrophil infiltration
after experimental myocardial infarction
(MI). Neutrophil infiltration in the myocar-
dium 1 day after MI by esterase-staining
(A) and quantification (B) and MPO-stain-
ing (C) and -quantification (D) of fast
degradable hydrogel slow degradable hy-
drogel (FDH SDH), Met-CCL5-FDH,
CXCL12 (S4V)-FDH and Met-CCL5-
FDH+CXCL12 (S4V)-FDH-treated mice
(n = 6–9 per group). Insets in (A) and (B)
show negative control staining; scale bars:
50 lm. Depicted P values are based on
non-parametric ANOVA (n ≥ 6).
796 ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
might be the rapid cleavage by MMP-2, resulting in a tetrapeptide and
a neurotoxic CXCL12 remnant [25]. Until now, the physiological role
of this cleavage is unknown, yet CXCL12 inactivation by MMPs stops
mobilization of hematopoietic stem cells from the bone marrow [13].
Up-regulation of MMP-2 after MI is well known and plays an impor-
tant role in the extracellular matrix turnover and remodelling [26].
Therefore, to sustain the CXCL12 function in vivo, it is essential to
block its degradation. For our herein described mouse in vivo study,
we implemented a previously described protease-resistant CXCL12
variant to investigate the improvement of cardiac function after MI
[13]. When incorporated into a slowly degradable hydrogel, CXCL12
is released gradually over a longer time period, assuring a local high
amount of chemokine and a continuous recruitment of stem cells.
Accordingly, neo-angiogenesis after MI was increased after treatment
with CXCL12 (S4V)-containing hydrogels, demonstrating the effi-
ciency of the treatment. Although CXCL12 is also involved in retaining
neutrophils in the bone marrow [27], the exogenous addition of
CXCL12 would increase the amount of circulating neutrophils. How-
ever, as the biodegradable hydrogel warrants a local and controlled
action of CXCL12, this pro-inflammatory function of CXCL12 is
expected to be minor in our experimental setting.
On the other hand, to reduce inflammation induced by MI,
recombinant Met-CCL5 was used to inhibit neutrophil infiltration. It
is well-established that CXCL8 and CCL5 are strong agonists for
neutrophil recruitment. Met-CCL5 is able to antagonize the actions
of CCL5 not only in vitro but also in vivo [8]. As the infiltration of
neutrophils occurs only for a short time period [23], we combined
Met-CCL5 with a very quickly biodegradable hydrogel, which
A
C
D
B
Fig. 4 Assessment of angiogenesis after
experimental myocardial infarction (MI).
Neovascularization as quantified by repre-
sentative CD31 staining 4 weeks after MI
(A) and quantification (B) of fast degrad-
able hydrogel slow degradable hydrogel
(FDH SDH), Met-CCL5-FDH, CXCL12
(S4V)-FDH and Met-CCL5-FDH+CXCL12
(S4V)-FDH-treated mice (n = 6–9 per
group). Examples of stained capillaries are
marked with triangles; scale bars: 50 lm.
Depicted P values are based on paramet-
ric ANOVA (n ≥ 6). Immunohistological
staining of total Akt (green) and phos-
phorylated (phospho-) Akt (red), 1 day
(C) and 4 weeks (D) after MI. Insets rep-
resent negative controls; scale bars:
50 lm.
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assures the release of this antagonist only for several hours. This
is essential to avoid the blocking of later functions of CCL5,
e.g. over CCR5, such as recruitment of reparatory monocytes or
T regulatory cells [28], which is necessary for a proper healing and
scar formation.
By the combined treatment with both recombinant chemokines
formulated in a time-dependent degradable hydrogel, we signifi-
cantly preserved the heart function and improved remodelling of
the ventricle. The cardioprotective effects of the Met-CCL5 and
protease-resistant CXCL12 are mediated through reduced infiltra-
tion of neutrophils in the infarcted myocardium, reduced apopto-
sis and increased recruitment of hematopoietic stem cells
respectively. Indeed, we found a decreased neutrophil infiltration
after treatment with Met-CCL5-FDH, and after combined treatment
with Met-CCL5-FDH and protease-resistant CXCL12 (S4V)-SDH.
These results are comparable with those found in CCR1-deficient
mice, or after anti-CCL5 mAb treatment, which showed that the
initial inhibition of CCL5 during early MI is cardioprotective owing
to its anti-inflammatory effects [8, 9], reducing both infarct size
and post-infarction heart failure in mouse model of chronic car-
diac ischaemia [29].
Moreover, increased angiogenesis was noticed after CXCL12
(S4V)-SDH alone and combined CXCL12 (S4V)-SDH and Met-CCL5-
FDH treatment, suggesting that the preserved ability of protease-
resistant CXCL12 mediated stem cell recruitment through its
CXCR4 receptor, which might be demonstrated by the increased
phosho-Akt staining in the CXCL12-treated groups. As expected,
Met-CCL5 alone was not able to promote angiogenesis. However,
although a decrease in infarction size was observed in all treated
groups, it appears that only combined treatment with CXCL12
(S4V) and Met-CCL5 is able to additionally improve the heart func-
tion and to assure the best healing and remodelling of the ventricle
after MI.
Conclusions
In summary, our study provides evidence that the combined therapy
of the protease-resistant CXCL12-SDH and Met-CCL5-FDH preserves
cardiac function, promotes angiogenesis and facilitates wound heal-
ing processes by attenuating neutrophil-induced myocardial inflam-
mation, representing an advantage over established separate
therapies implementing CXCL12 and Met-CCL5. This novel strategy
might constitute an additional option to optimize cardiac repair and
remodelling after myocardial injury and might complement cell-based
therapies.
A B
C D
Fig. 5 Assessment of apoptosis and prolif-
eration after experimental myocardial
infarction (MI). Proliferating cells were
stained with Ki67 and quantified as per
cent from total cells, 1 day (black bars)
and 4 weeks (white bars) after MI (A).
Representative pictures of positive Ki67
staining 4 weeks after MI are showed (B,
DAPI staining in insets). Apoptotic cells
were stained and quantified as per cent of
total cells, 1 day (black bars) or 4 weeks
(white bars) after MI (C). Representative
pictures of positive TUNEL staining 1 day
after MI are shown (D, DAPI staining in
insets); scale bars: 50 lm. Depicted P
values are based on parametric ANOVA
(n ≥ 6).
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